1. Home
  2. GOTU vs MNPR Comparison

GOTU vs MNPR Comparison

Compare GOTU & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GOTU

Gaotu Techedu Inc.

N/A

Current Price

$2.54

Market Cap

578.2M

Sector

Real Estate

ML Signal

N/A

Logo Monopar Therapeutics Inc.

MNPR

Monopar Therapeutics Inc.

N/A

Current Price

$72.31

Market Cap

587.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GOTU
MNPR
Founded
2014
2014
Country
China
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
578.2M
587.4M
IPO Year
2019
2019

Fundamental Metrics

Financial Performance
Metric
GOTU
MNPR
Price
$2.54
$72.31
Analyst Decision
Strong Buy
Buy
Analyst Count
5
12
Target Price
$3.74
★ $129.92
AVG Volume (30 Days)
★ 506.3K
118.4K
Earning Date
11-25-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 54.99
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$15.06
N/A
Revenue Next Year
$13.44
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.40
$50.07
52 Week High
$3.05
$124.82

Technical Indicators

Market Signals
Indicator
GOTU
MNPR
Relative Strength Index (RSI) 51.66 35.57
Support Level $2.02 $68.81
Resistance Level $2.87 $76.13
Average True Range (ATR) 0.10 3.42
MACD -0.04 0.77
Stochastic Oscillator 18.52 22.03

Price Performance

Historical Comparison
GOTU
MNPR

About GOTU Gaotu Techedu Inc.

Gaotu Techedu Inc is a technology-driven education company in China that enables lifelong learning through AI-powered solutions that cultivate interest and drive continuous growth. The Company provides AI-powered, product-led learning solutions for learners from pre-school to adulthood. By combining rare, high-caliber teaching resources with AI-enhanced tools and content, Gaotu creates engaging and effective learning experiences delivered through both online and offline channels. AI and data analytics permeate the Company's operations, adapting content and teaching methods to individual learner needs, improving efficiency, and driving sustained learning progress.

About MNPR Monopar Therapeutics Inc.

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.

Share on Social Networks: